.gif)
Philips India and Ion Beam Applications S.A. (IBA), a global leader in proton therapy for the treatment of cancer, signed an exclusive agreement to enhance access to proton therapy in India. The collaboration also enables both organizations to mutually leverage technologies and solutions. Two companies have already signed multiple country-specific collaboration agreements, each optimized for the local market needs.The alliance combines Philips’ expertise and innovative imaging techniques for strengths in proton therapy.
Philips will adopt the proton therapy solutions within its offering for customers in select markets globally. In fact, the agreement builds upon the collaboration between Philips India and IBA, which started in 2013, to build the Apollo Proton Therapy Centre, the first proton therapy centre in India.
Advanced MRI, PET and CT imaging technologies will help physicians better target proton beam delivery to destroy cancer cells whilst avoiding healthy tissue. Proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment. Proton therapy is an important addition to cancer treatment in India given that the incidence of cancer is 70-90 per 100,000 people with children comprising nearly 5 per cent of these patients. The treatment is particularly appropriate for eye and brain cancers. Tumors close to the brain stem and spinal cord as well as prostate, liver, lung cancers are well suited for proton therapy besides paediatric cancers.
Subscribe to PharmaTutor News Alerts by Email >>
